CA2836373A1 - Mcam antagonists and methods of treatment - Google Patents

Info

Publication number

CA2836373A1

CA2836373A1 CA2836373A CA2836373A CA2836373A1 CA 2836373 A1 CA2836373 A1 CA 2836373A1 CA 2836373 A CA2836373 A CA 2836373A CA 2836373 A CA2836373 A CA 2836373A CA 2836373 A1 CA2836373 A1 CA 2836373A1

Authority

CA

Canada

Prior art keywords

mcam

antibody

seq

amino acid

acid sequence

Prior art date

2011-06-06

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 239000005557 antagonist Substances 0.000 title claims abstract description 106
• 238000000034 method Methods 0.000 title claims description 107
• 238000011282 treatment Methods 0.000 title claims description 36
• 101150094768 Mcam gene Proteins 0.000 title description 2
• 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims abstract description 386
• 210000003169 central nervous system Anatomy 0.000 claims abstract description 77
• 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 claims abstract description 56
• 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 54
• 230000008595 infiltration Effects 0.000 claims abstract description 33
• 238000001764 infiltration Methods 0.000 claims abstract description 33
• 230000002314 neuroinflammatory effect Effects 0.000 claims abstract description 30
• 208000018737 Parkinson disease Diseases 0.000 claims abstract description 26
• 206010015866 Extravasation Diseases 0.000 claims abstract description 8
• 230000036251 extravasation Effects 0.000 claims abstract description 8
• PJOHVEQSYPOERL-SHEAVXILSA-N (e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-3-(4-methylphenyl)prop-2-enamide Chemical compound C1=CC(C)=CC=C1\C=C\C(=O)N[C@]1(CCC(=O)[C@@H]2O3)[C@H]4CC5=CC=C(O)C3=C5[C@]12CCN4CC1CC1 PJOHVEQSYPOERL-SHEAVXILSA-N 0.000 claims abstract 37
• 210000004027 cell Anatomy 0.000 claims description 134
• 230000027455 binding Effects 0.000 claims description 123
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 86
• 241000282414 Homo sapiens Species 0.000 claims description 84
• 108091007433 antigens Proteins 0.000 claims description 70
• 102000036639 antigens Human genes 0.000 claims description 70
• 239000000427 antigen Substances 0.000 claims description 69
• 239000012634 fragment Substances 0.000 claims description 53
• 108060003951 Immunoglobulin Proteins 0.000 claims description 24
• 102000018358 immunoglobulin Human genes 0.000 claims description 24
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 20
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 20
• 208000027866 inflammatory disease Diseases 0.000 claims description 18
• 102000051110 human MCAM Human genes 0.000 claims description 16
• 238000004519 manufacturing process Methods 0.000 claims description 13
• 239000003814 drug Substances 0.000 claims description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims description 11
• 210000002889 endothelial cell Anatomy 0.000 claims description 9
• 230000005764 inhibitory process Effects 0.000 claims description 3
• 239000003446 ligand Substances 0.000 abstract description 54
• 230000003993 interaction Effects 0.000 abstract description 22
• 230000002401 inhibitory effect Effects 0.000 abstract description 16
• 108010025714 CD146 Antigen Proteins 0.000 description 347
• 108010085895 Laminin Proteins 0.000 description 102
• 102000007547 Laminin Human genes 0.000 description 102
• 210000001744 T-lymphocyte Anatomy 0.000 description 84
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 66
• 201000010099 disease Diseases 0.000 description 41
• 108090000765 processed proteins & peptides Proteins 0.000 description 39
• 108090000623 proteins and genes Proteins 0.000 description 38
• 230000014509 gene expression Effects 0.000 description 35
• 102000004196 processed proteins & peptides Human genes 0.000 description 32
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 30
• 208000023275 Autoimmune disease Diseases 0.000 description 30
• 235000001014 amino acid Nutrition 0.000 description 29
• 229920001184 polypeptide Polymers 0.000 description 29
• 229940024606 amino acid Drugs 0.000 description 28
• 150000001413 amino acids Chemical class 0.000 description 28
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 28
• 102000004169 proteins and genes Human genes 0.000 description 26
• 208000035475 disorder Diseases 0.000 description 25
• 102000004127 Cytokines Human genes 0.000 description 24
• 108090000695 Cytokines Proteins 0.000 description 24
• 235000018102 proteins Nutrition 0.000 description 24
• 241000699670 Mus sp. Species 0.000 description 23
• 238000003556 assay Methods 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 22
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 20
• 102000013691 Interleukin-17 Human genes 0.000 description 20
• 238000012360 testing method Methods 0.000 description 19
• 241000699666 Mus <mouse, genus> Species 0.000 description 18
• 125000000539 amino acid group Chemical group 0.000 description 18
• 230000004071 biological effect Effects 0.000 description 18
• 230000001684 chronic effect Effects 0.000 description 18
• 150000001875 compounds Chemical class 0.000 description 18
• 238000006467 substitution reaction Methods 0.000 description 18
• 239000000463 material Substances 0.000 description 17
• 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 15
• 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 15
• 230000001363 autoimmune Effects 0.000 description 15
• 239000000203 mixture Substances 0.000 description 15
• 241001465754 Metazoa Species 0.000 description 14
• 241001529936 Murinae Species 0.000 description 14
• 208000024891 symptom Diseases 0.000 description 14
• 230000001965 increasing effect Effects 0.000 description 13
• 230000000750 progressive effect Effects 0.000 description 13
• 230000000694 effects Effects 0.000 description 12
• 210000004408 hybridoma Anatomy 0.000 description 12
• 208000011580 syndromic disease Diseases 0.000 description 12
• 206010028980 Neoplasm Diseases 0.000 description 11
• 210000002469 basement membrane Anatomy 0.000 description 11
• 238000002474 experimental method Methods 0.000 description 11
• 238000010186 staining Methods 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 10
• 230000006870 function Effects 0.000 description 10
• 230000001404 mediated effect Effects 0.000 description 10
• 210000003071 memory t lymphocyte Anatomy 0.000 description 10
• 150000007523 nucleic acids Chemical group 0.000 description 10
• 230000001154 acute effect Effects 0.000 description 9
• 206010003246 arthritis Diseases 0.000 description 9
• 238000010494 dissociation reaction Methods 0.000 description 9
• 230000005593 dissociations Effects 0.000 description 9
• 238000005516 engineering process Methods 0.000 description 9
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• 201000011510 cancer Diseases 0.000 description 8
• 239000012636 effector Substances 0.000 description 8
• -1 his Chemical compound 0.000 description 8
• 102000006495 integrins Human genes 0.000 description 8
• 108010044426 integrins Proteins 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 230000009870 specific binding Effects 0.000 description 8
• 210000000278 spinal cord Anatomy 0.000 description 8
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
• 102100027581 Forkhead box protein P3 Human genes 0.000 description 7
• 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 7
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 7
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
• 210000004556 brain Anatomy 0.000 description 7
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
• 210000002987 choroid plexus Anatomy 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 210000002744 extracellular matrix Anatomy 0.000 description 7
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
• 229940072221 immunoglobulins Drugs 0.000 description 7
• 201000001441 melanoma Diseases 0.000 description 7
• 238000007423 screening assay Methods 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• 102100036848 C-C motif chemokine 20 Human genes 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 6
• 206010061218 Inflammation Diseases 0.000 description 6
• 101100458667 Mus musculus Mcam gene Proteins 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 230000000903 blocking effect Effects 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 102000039446 nucleic acids Human genes 0.000 description 6
• 108020004707 nucleic acids Proteins 0.000 description 6
• 230000007170 pathology Effects 0.000 description 6
• 238000002823 phage display Methods 0.000 description 6
• 238000003752 polymerase chain reaction Methods 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 150000003384 small molecules Chemical class 0.000 description 6
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 6
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 5
• 208000015943 Coeliac disease Diseases 0.000 description 5
• 206010061818 Disease progression Diseases 0.000 description 5
• 238000002965 ELISA Methods 0.000 description 5
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
• 241000288906 Primates Species 0.000 description 5
• 201000004681 Psoriasis Diseases 0.000 description 5
• 206010047115 Vasculitis Diseases 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 208000010668 atopic eczema Diseases 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 230000005750 disease progression Effects 0.000 description 5
• 238000000684 flow cytometry Methods 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 210000000265 leukocyte Anatomy 0.000 description 5
• 230000001394 metastastic effect Effects 0.000 description 5
• 206010061289 metastatic neoplasm Diseases 0.000 description 5
• 230000005012 migration Effects 0.000 description 5
• 238000013508 migration Methods 0.000 description 5
• 238000002703 mutagenesis Methods 0.000 description 5
• 231100000350 mutagenesis Toxicity 0.000 description 5
• 239000013642 negative control Substances 0.000 description 5
• 230000001717 pathogenic effect Effects 0.000 description 5
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
• 230000010287 polarization Effects 0.000 description 5
• 230000000069 prophylactic effect Effects 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• 210000004988 splenocyte Anatomy 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• 241000282693 Cercopithecidae Species 0.000 description 4
• 206010011878 Deafness Diseases 0.000 description 4
• 208000029523 Interstitial Lung disease Diseases 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
• 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 4
• 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 4
• 108091028043 Nucleic acid sequence Proteins 0.000 description 4
• 206010034277 Pemphigoid Diseases 0.000 description 4
• 206010044565 Tremor Diseases 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 235000004279 alanine Nutrition 0.000 description 4
• 230000000172 allergic effect Effects 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 230000006720 chronic neuroinflammation Effects 0.000 description 4
• 230000008045 co-localization Effects 0.000 description 4
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
• 229940000406 drug candidate Drugs 0.000 description 4
• 230000003511 endothelial effect Effects 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 208000016354 hearing loss disease Diseases 0.000 description 4
• 210000002865 immune cell Anatomy 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 108010038862 laminin 10 Proteins 0.000 description 4
• 239000003094 microcapsule Substances 0.000 description 4
• 230000003959 neuroinflammation Effects 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 230000001575 pathological effect Effects 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 210000005166 vasculature Anatomy 0.000 description 4
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 3
• 206010011715 Cyclitis Diseases 0.000 description 3
• 206010012442 Dermatitis contact Diseases 0.000 description 3
• 206010014950 Eosinophilia Diseases 0.000 description 3
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 3
• 208000024869 Goodpasture syndrome Diseases 0.000 description 3
• 201000005569 Gout Diseases 0.000 description 3
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
• 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 3
• 206010021263 IgA nephropathy Diseases 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• 206010025280 Lymphocytosis Diseases 0.000 description 3
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 206010061309 Neoplasm progression Diseases 0.000 description 3
• 206010029164 Nephrotic syndrome Diseases 0.000 description 3
• 108091034117 Oligonucleotide Proteins 0.000 description 3
• 201000011152 Pemphigus Diseases 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 206010039705 Scleritis Diseases 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 241000282898 Sus scrofa Species 0.000 description 3
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
• 208000003441 Transfusion reaction Diseases 0.000 description 3
• 108700019146 Transgenes Proteins 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 210000001642 activated microglia Anatomy 0.000 description 3
• 208000007502 anemia Diseases 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 230000008499 blood brain barrier function Effects 0.000 description 3
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 229920001577 copolymer Polymers 0.000 description 3
• 230000002354 daily effect Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 230000010370 hearing loss Effects 0.000 description 3
• 231100000888 hearing loss Toxicity 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 230000024949 interleukin-17 production Effects 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 238000010208 microarray analysis Methods 0.000 description 3
• 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 201000008383 nephritis Diseases 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 230000007918 pathogenicity Effects 0.000 description 3
• 208000033808 peripheral neuropathy Diseases 0.000 description 3
• 230000035699 permeability Effects 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000000770 proinflammatory effect Effects 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 208000002574 reactive arthritis Diseases 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 230000007115 recruitment Effects 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 230000006641 stabilisation Effects 0.000 description 3
• 238000011105 stabilization Methods 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 230000005751 tumor progression Effects 0.000 description 3
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 2
• 206010001889 Alveolitis Diseases 0.000 description 2
• 208000035939 Alveolitis allergic Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000004300 Atrophic Gastritis Diseases 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 208000006373 Bell palsy Diseases 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• 108700031361 Brachyury Proteins 0.000 description 2
• 206010006100 Bradykinesia Diseases 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 241000700199 Cavia porcellus Species 0.000 description 2
• 208000031976 Channelopathies Diseases 0.000 description 2
• 102000009410 Chemokine receptor Human genes 0.000 description 2
• 108050000299 Chemokine receptor Proteins 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 206010008909 Chronic Hepatitis Diseases 0.000 description 2
• 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• 206010051392 Diapedesis Diseases 0.000 description 2
• 208000003164 Diplopia Diseases 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 201000003542 Factor VIII deficiency Diseases 0.000 description 2
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 206010018634 Gouty Arthritis Diseases 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 208000009292 Hemophilia A Diseases 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 208000006083 Hypokinesia Diseases 0.000 description 2
• 208000000038 Hypoparathyroidism Diseases 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 102000001749 Immunologic Receptors Human genes 0.000 description 2
• 108010054738 Immunologic Receptors Proteins 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102000013462 Interleukin-12 Human genes 0.000 description 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
• 108010000817 Leuprolide Proteins 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
• 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 2
• 208000002740 Muscle Rigidity Diseases 0.000 description 2
• 208000000112 Myalgia Diseases 0.000 description 2
• 206010028424 Myasthenic syndrome Diseases 0.000 description 2
• 102000006386 Myelin Proteins Human genes 0.000 description 2
• 108010083674 Myelin Proteins Proteins 0.000 description 2
• 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 2
• 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 2
• 201000002481 Myositis Diseases 0.000 description 2
• 206010028665 Myxoedema Diseases 0.000 description 2
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
• 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
• 206010029240 Neuritis Diseases 0.000 description 2
• 208000008457 Neurologic Manifestations Diseases 0.000 description 2
• 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 206010033645 Pancreatitis Diseases 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 241000721454 Pemphigus Species 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
• 206010065159 Polychondritis Diseases 0.000 description 2
• 206010036105 Polyneuropathy Diseases 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• 208000032023 Signs and Symptoms Diseases 0.000 description 2
• 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 108700012920 TNF Proteins 0.000 description 2
• 208000024780 Urticaria Diseases 0.000 description 2
• 206010047124 Vasculitis necrotising Diseases 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000009824 affinity maturation Effects 0.000 description 2
• 238000012867 alanine scanning Methods 0.000 description 2
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 208000002399 aphthous stomatitis Diseases 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
• 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
• 239000008228 bacteriostatic water for injection Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 238000012219 cassette mutagenesis Methods 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 230000005779 cell damage Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
• 208000024376 chronic urticaria Diseases 0.000 description 2
• 230000000536 complexating effect Effects 0.000 description 2
• 208000010247 contact dermatitis Diseases 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 201000003278 cryoglobulinemia Diseases 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 239000003405 delayed action preparation Substances 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 230000003292 diminished effect Effects 0.000 description 2
• 229960003638 dopamine Drugs 0.000 description 2
• 201000002491 encephalomyelitis Diseases 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• 208000030172 endocrine system disease Diseases 0.000 description 2
• 206010014801 endophthalmitis Diseases 0.000 description 2
• 239000005038 ethylene vinyl acetate Substances 0.000 description 2
• 230000003203 everyday effect Effects 0.000 description 2
• 238000000799 fluorescence microscopy Methods 0.000 description 2
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 2
• 230000004914 glial activation Effects 0.000 description 2
• 229960002743 glutamine Drugs 0.000 description 2
• 208000007475 hemolytic anemia Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 108010046591 human laminin-511 Proteins 0.000 description 2
• 102000007573 human laminin-511 Human genes 0.000 description 2
• 239000000017 hydrogel Substances 0.000 description 2
• 208000003532 hypothyroidism Diseases 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000004968 inflammatory condition Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 108010057717 laminin 8 Proteins 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 201000002364 leukopenia Diseases 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 238000009593 lumbar puncture Methods 0.000 description 2
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 238000002493 microarray Methods 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 208000037890 multiple organ injury Diseases 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 210000005012 myelin Anatomy 0.000 description 2
• 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 2
• 208000003786 myxedema Diseases 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 238000006386 neutralization reaction Methods 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 208000005963 oophoritis Diseases 0.000 description 2
• 201000005737 orchitis Diseases 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 208000035824 paresthesia Diseases 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
• 201000006292 polyarteritis nodosa Diseases 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 230000007824 polyneuropathy Effects 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000004850 protein–protein interaction Effects 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 201000009890 sinusitis Diseases 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 206010043554 thrombocytopenia Diseases 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
• XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
• 102100033051 40S ribosomal protein S19 Human genes 0.000 description 1
• BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
• XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
• 206010001076 Acute sinusitis Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
• 206010062269 Adrenalitis Diseases 0.000 description 1
• 201000010000 Agranulocytosis Diseases 0.000 description 1
• WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
• YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 206010001766 Alopecia totalis Diseases 0.000 description 1
• 208000024985 Alport syndrome Diseases 0.000 description 1
• 206010001881 Alveolar proteinosis Diseases 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 206010002961 Aplasia Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• BHSYMWWMVRPCPA-CYDGBPFRSA-N Arg-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N BHSYMWWMVRPCPA-CYDGBPFRSA-N 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003267 Arthritis reactive Diseases 0.000 description 1
• PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
• LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
• KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
• FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
• 201000002909 Aspergillosis Diseases 0.000 description 1
• 208000036641 Aspergillus infections Diseases 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 208000012657 Atopic disease Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 206010003805 Autism Diseases 0.000 description 1
• 208000020706 Autistic disease Diseases 0.000 description 1
• 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
• 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 201000007155 CD40 ligand deficiency Diseases 0.000 description 1
• 201000002829 CREST Syndrome Diseases 0.000 description 1
• 208000004434 Calcinosis Diseases 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 208000020119 Caplan syndrome Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 208000002691 Choroiditis Diseases 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• 206010009137 Chronic sinusitis Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 102100026735 Coagulation factor VIII Human genes 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000010007 Cogan syndrome Diseases 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 102000000503 Collagen Type II Human genes 0.000 description 1
• 108010041390 Collagen Type II Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 241001573498 Compacta Species 0.000 description 1
• 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
• 206010010619 Congenital rubella infection Diseases 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• 206010011686 Cutaneous vasculitis Diseases 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 208000001490 Dengue Diseases 0.000 description 1
• 206010012310 Dengue fever Diseases 0.000 description 1
• 206010012434 Dermatitis allergic Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
• 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
• 208000021866 Dressler syndrome Diseases 0.000 description 1
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
• 206010013774 Dry eye Diseases 0.000 description 1
• 208000001708 Dupuytren contracture Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 208000005235 Echovirus Infections Diseases 0.000 description 1
• 206010014201 Eczema nummular Diseases 0.000 description 1
• 208000037487 Endotoxemia Diseases 0.000 description 1
• 208000004232 Enteritis Diseases 0.000 description 1
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
• 206010015084 Episcleritis Diseases 0.000 description 1
• 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• 206010015251 Erythroblastosis foetalis Diseases 0.000 description 1
• 208000030644 Esophageal Motility disease Diseases 0.000 description 1
• 208000004332 Evans syndrome Diseases 0.000 description 1
• 208000009386 Experimental Arthritis Diseases 0.000 description 1
• 208000027445 Farmer Lung Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000028387 Felty syndrome Diseases 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• 206010016952 Food poisoning Diseases 0.000 description 1
• 208000019331 Foodborne disease Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000036495 Gastritis atrophic Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 208000008899 Habitual abortion Diseases 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
• 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
• 101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 description 1
• 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 206010058359 Hypogonadism Diseases 0.000 description 1
• 206010021067 Hypopituitarism Diseases 0.000 description 1
• 208000031814 IgA Vasculitis Diseases 0.000 description 1
• IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
• IPFKIGNDTUOFAF-CYDGBPFRSA-N Ile-Val-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IPFKIGNDTUOFAF-CYDGBPFRSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 description 1
• 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
• 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
• 208000004575 Infectious Arthritis Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 238000012695 Interfacial polymerization Methods 0.000 description 1
• 206010022557 Intermediate uveitis Diseases 0.000 description 1
• 206010022941 Iridocyclitis Diseases 0.000 description 1
• 208000000209 Isaacs syndrome Diseases 0.000 description 1
• 208000009388 Job Syndrome Diseases 0.000 description 1
• 208000012528 Juvenile dermatomyositis Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 206010023335 Keratitis interstitial Diseases 0.000 description 1
• 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 208000004554 Leishmaniasis Diseases 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• LCPYQJIKPJDLLB-UWVGGRQHSA-N Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C LCPYQJIKPJDLLB-UWVGGRQHSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
• 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
• 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 description 1
• 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 206010025102 Lung infiltration Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 239000004907 Macro-emulsion Substances 0.000 description 1
• 206010025598 Malignant hydatidiform mole Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000005647 Mumps Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 208000010428 Muscle Weakness Diseases 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 102000047918 Myelin Basic Human genes 0.000 description 1
• 102000055324 Myelin Proteolipid Human genes 0.000 description 1
• 101710107068 Myelin basic protein Proteins 0.000 description 1
• 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 206010065673 Nephritic syndrome Diseases 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• 208000007256 Nevus Diseases 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 206010033892 Paraplegia Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 208000008071 Parvoviridae Infections Diseases 0.000 description 1
• 206010057343 Parvovirus infection Diseases 0.000 description 1
• 208000026433 Pemphigus erythematosus Diseases 0.000 description 1
• 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
• KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
• 201000007131 Placental site trophoblastic tumor Diseases 0.000 description 1
• 206010036030 Polyarthritis Diseases 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• 206010036242 Post vaccination syndrome Diseases 0.000 description 1
• 206010036297 Postpartum hypopituitarism Diseases 0.000 description 1
• 206010036631 Presenile dementia Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 206010036697 Primary hypothyroidism Diseases 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 206010037575 Pustular psoriasis Diseases 0.000 description 1
• 206010037714 Quadriplegia Diseases 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 208000021329 Refractory celiac disease Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 206010071390 Resting tremor Diseases 0.000 description 1
• 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241001303601 Rosacea Species 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
• 206010040026 Sensory disturbance Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
• XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
• DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
• 201000009895 Sheehan syndrome Diseases 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
• 206010042342 Subcorneal pustular dermatosis Diseases 0.000 description 1
• 208000010265 Sweet syndrome Diseases 0.000 description 1
• 208000027522 Sydenham chorea Diseases 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 206010043781 Thyroiditis chronic Diseases 0.000 description 1
• 206010043784 Thyroiditis subacute Diseases 0.000 description 1
• 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
• 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 206010051446 Transient acantholytic dermatosis Diseases 0.000 description 1
• 208000006391 Type 1 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 1
• 206010070517 Type 2 lepra reaction Diseases 0.000 description 1
• ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010047112 Vasculitides Diseases 0.000 description 1
• 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000014926 Vesiculobullous Skin disease Diseases 0.000 description 1
• 206010047513 Vision blurred Diseases 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 239000003929 acidic solution Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000026816 acute arthritis Diseases 0.000 description 1
• 201000004073 acute interstitial pneumonia Diseases 0.000 description 1
• 230000004721 adaptive immunity Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 208000002029 allergic contact dermatitis Diseases 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 201000010435 allergic urticaria Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 206010002022 amyloidosis Diseases 0.000 description 1
• 201000004612 anterior uveitis Diseases 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 201000009361 ascariasis Diseases 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 125000000613 asparagine group Chemical class N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 208000001974 autoimmune enteropathy Diseases 0.000 description 1
• 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 208000015440 bird fancier lung Diseases 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000007541 cellular toxicity Effects 0.000 description 1
• 208000010353 central nervous system vasculitis Diseases 0.000 description 1
• 208000025434 cerebellar degeneration Diseases 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 230000001055 chewing effect Effects 0.000 description 1
• 201000010415 childhood type dermatomyositis Diseases 0.000 description 1
• 201000004709 chorioretinitis Diseases 0.000 description 1
• 208000030949 chronic idiopathic urticaria Diseases 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
• 206010072757 chronic spontaneous urticaria Diseases 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000000749 co-immunoprecipitation Methods 0.000 description 1
• 238000005354 coacervation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 210000005220 cytoplasmic tail Anatomy 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 238000011157 data evaluation Methods 0.000 description 1
• 231100000895 deafness Toxicity 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 208000025729 dengue disease Diseases 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 201000010064 diabetes insipidus Diseases 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 208000032625 disorder of ear Diseases 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 208000029444 double vision Diseases 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 201000011191 dyskinesia of esophagus Diseases 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000006862 enzymatic digestion Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 201000009320 ethmoid sinusitis Diseases 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 208000004526 exfoliative dermatitis Diseases 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 208000022195 farmer lung disease Diseases 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 208000001031 fetal erythroblastosis Diseases 0.000 description 1
• 201000006916 frontal sinusitis Diseases 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 201000001505 hemoglobinuria Diseases 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• 208000003215 hereditary nephritis Diseases 0.000 description 1
• 238000013537 high throughput screening Methods 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 210000004754 hybrid cell Anatomy 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 description 1
• 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
• 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 description 1
• 230000003463 hyperproliferative effect Effects 0.000 description 1
• 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 208000018879 impaired coordination Diseases 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 201000006747 infectious mononucleosis Diseases 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 210000004692 intercellular junction Anatomy 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 108010027445 interleukin-22 receptor Proteins 0.000 description 1
• 210000003962 intermediate trophoblast Anatomy 0.000 description 1
• 201000006904 interstitial keratitis Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000037041 intracellular level Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 208000001875 irritant dermatitis Diseases 0.000 description 1
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
• 208000018937 joint inflammation Diseases 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 238000012004 kinetic exclusion assay Methods 0.000 description 1
• 108010057697 laminin 9 Proteins 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• 108010091798 leucylleucine Proteins 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 208000029631 linear IgA Dermatosis Diseases 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229940087857 lupron Drugs 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 201000008836 maxillary sinusitis Diseases 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 210000002752 melanocyte Anatomy 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 210000000274 microglia Anatomy 0.000 description 1
• 206010063344 microscopic polyangiitis Diseases 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
• 208000010805 mumps infectious disease Diseases 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 208000009928 nephrosis Diseases 0.000 description 1
• 231100001027 nephrosis Toxicity 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000009251 neurologic dysfunction Effects 0.000 description 1
• 230000007971 neurological deficit Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 208000002040 neurosyphilis Diseases 0.000 description 1
• 201000004071 non-specific interstitial pneumonia Diseases 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 208000028780 ocular motility disease Diseases 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 208000029308 periodic paralysis Diseases 0.000 description 1
• 230000008823 permeabilization Effects 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000008180 pharmaceutical surfactant Substances 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 201000008824 placental choriocarcinoma Diseases 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 208000030428 polyarticular arthritis Diseases 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 208000006473 polyradiculopathy Diseases 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000002516 postimmunization Effects 0.000 description 1
• 230000001144 postural effect Effects 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 201000003489 pulmonary alveolar proteinosis Diseases 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
• 206010061928 radiculitis Diseases 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 208000009169 relapsing polychondritis Diseases 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 201000004700 rosacea Diseases 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 201000004409 schistosomiasis Diseases 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 208000008742 seborrheic dermatitis Diseases 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 201000001223 septic arthritis Diseases 0.000 description 1
• 208000013223 septicemia Diseases 0.000 description 1
• 201000006476 shipyard eye Diseases 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 230000005808 skin problem Effects 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 208000010485 smooth muscle tumor Diseases 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 201000006923 sphenoid sinusitis Diseases 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 201000007497 subacute thyroiditis Diseases 0.000 description 1
• 210000003523 substantia nigra Anatomy 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 208000002025 tabes dorsalis Diseases 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 208000008732 thymoma Diseases 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 208000005057 thyrotoxicosis Diseases 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 230000007838 tissue remodeling Effects 0.000 description 1
• 230000005100 tissue tropism Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1